Pneumococcal conjugate vaccines - Implications for community antibiotic prescribing

Current Opinion in Microbiology

Volumn 3, Issue 5, 2000, Pages 502-507

  Tan, Tina Q ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; PRESCRIPTION; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

BACTERIA (MICROORGANISMS); PNEUMOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0033787582     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(00)00130-2     Document Type: Review

References (47)

1. The burden of pneumococcal disease: The role of conjugate vaccines
2. The epidemiology of pneumococcal infection in children in the developing world
3. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
4. Three-year multicenter surveillance of systemic pneumococcal infections in children
5. Drug-resistant Streptococcus pneumoniae
6. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial surveillance program
7. Acute otitis media: Management and surveillance in an era of pneumococcal resistance - A report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group
8. Therapy for children with invasive pneumococcal infections
9. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group
10. Antibiotics for Gram-positive bacterial infections: Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid
11. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: Current antibiotic therapy in the 1990s
12. Dynamics of nasopharygeal colonization by Streptococcus pneumoniae
13. Streptococcus pneumoniae colonization in the young child: Association with otitis media and resistance to penicillin
14. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae
15. Etiology and treatment of pneumonia
16. Pediatric pneumococcal bone and joint infections
17. Three-year multicenter surveillance of pneumococcal meningitis in children: Clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use
18. Streptococccus pneumoniae: Its role in childhood illness
19. Acute community-acquired sinusitis
20. Intramuscular vs. oral antibiotic therapy for the prevention of meningitis and other bacterial sequelae in young, febrile children at risk for occult bacteremia
21. Complicated parapneumonic effusions in children caused by penicillin non-susceptible Streptococcus pneumoniae
22. Pneumococcal meningitis in children: Prognostic indicators and outcome
23. Bacterial meningitis in the United States in 1995
24. Streptococcus pneumoniae: Impact of antibiotic resistance in pediatrics
25. Serogroup-specific epidemiology of Streptococcus pneumoniae: Associations with age, sex, geography in 7000 episodes of invasive disease
26. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, Part I
27. Nasopharyngeal colonization in Southern Israel with antibiotic-resistant pneumococci during the first two years of life: Relation to serotypes likely to be included in pneumococcal conjugate vaccines
28. Pneumococcal vaccines: History, current status, and future directions
29. The contribution of specific pneumococcal serogroups to different disease manifestations: Implications for conjugate vaccine formulation and use, part II
30. Epidemiology of pneumococcal serotypes and conjugate vaccine formulations
31. Advances in pneumococcal vaccines
32. Pneumococcal vaccine: An update
33. Pneumococcal vaccine
34. Pneumococcal conjugate vaccines
35. 197 conjugate vaccine in infants and toddlers
36. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants
37. Immunogenicity of pneumococcal conjugate vaccines
38. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines
39. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory
40. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children
41. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
42. Carriage of pneumococci after pneumococcal vaccination
43. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
44. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
45. Effect of a 9-valent pneumococcal vaccine on nasopharyngeal carriage of vaccine type and non-vaccine type S. pneumoniae strains among day care center attendees
46. Conjugate pneumococcal vaccine: The practical issues. CME Program Activity